The Global Tick-borne Encephalitis Inactivated Vaccine Market was valued at USD 286.5 Million in 2024 and is projected to reach USD 423.8 Million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 5.8% during the forecast period (2024–2030). This growth is being driven by increasing prevalence of tick-borne diseases, rising healthcare awareness in endemic regions, and the accelerating adoption of preventive vaccination programs across Europe and Asia-Pacific territories.

As global healthcare systems strengthen their defenses against vector-borne diseases, the spotlight is on the key vaccine manufacturers driving innovation, protection, and public health security. In this blog, we profile the Top 10 Companies in the Tick-borne Encephalitis Inactivated Vaccine Market—a mix of pharmaceutical leaders, biotechnology innovators, and public health pioneers shaping the future of infectious disease prevention.

---

🔟 1. Pfizer Inc.

Headquarters: New York, New York, USA
Key Offering: TicoVac (FSME-IMMUN), Adult and Pediatric Formulations

Pfizer is one of the world’s leading pharmaceutical companies developing and commercializing vaccines for infectious diseases. The company markets TicoVac, a highly effective inactivated vaccine providing protection against all three subtypes of TBE virus.

Innovation Initiatives:

• Proven efficacy across European and Siberian TBE virus strains

• Pediatric formulations available for children aged 1-15 years

• Extensive clinical trial programs supporting vaccine safety profiles

Download FREE Sample Report:
Tick-borne Encephalitis Inactivated Vaccine Market – View in Detailed Research Report

---

9️⃣ 2. Valneva SE

Headquarters: Saint-Herblain, France
Key Offering: TBE vaccine (Encepur), Rapid Immunization Schedule Options

Valneva specializes in developing and commercializing vaccines for infectious diseases with high unmet medical needs. Their TBE vaccine portfolio represents a significant component of their travel and endemic vaccines strategy.

Innovation Initiatives:

• Accelerated vaccination schedules for rapid protection

• Strategic focus on markets with high TBE incidence rates

---

8️⃣ 3. Baxter International Inc. (now part of Takeda)

Headquarters: Deerfield, Illinois, USA
Key Offering: Encepur (Adult and Children formulations)

Baxter’s vaccine division has been a longstanding provider of TBE vaccines, particularly strong in Central European markets where TBE represents a significant public health concern.

Innovation Initiatives:

• Highly purified, inactivated whole-virus TBE vaccines

• Pediatric formulations with established safety profiles

---

7️⃣ 4. GlaxoSmithKline (GSK)

Headquarters: Brentford, United Kingdom
Key Offering: Integrated vaccine portfolio including TBE protection solutions

GSK maintains a robust vaccine portfolio through strategic manufacturing and distribution partnerships. While not always the primary TBE vaccine manufacturer, GSK plays a crucial role in global vaccine distribution networks.

Innovation Initiatives:

• Travel medicine expertise supporting global vaccine access

• Support for national immunization programs in at-risk regions

---

6️⃣ 5. Merck & Co., Inc.

Headquarters: Kenilworth, New Jersey, USA
Key Offering: Comprehensive vaccine portfolio with TBE prevention capabilities

As a global healthcare leader, Merck provides essential vaccines through its established manufacturing infrastructure and global distribution capabilities.

Innovation Initiatives:

• Global vaccine supply chain management expertise

• Commitment to developing solutions for emerging infectious disease threats

Download FREE Sample Report:
Tick-borne Encephalitis Inactivated Vaccine Market – View in Detailed Research Report

---

5️⃣ 6. Bavarian Nordic A/S

Headquarters: Hellerup, Denmark
Key Offering: Specialized vaccine development platform with vector-borne disease applications

Bavarian Nordic focuses on developing vaccines for infectious diseases and cancer immunotherapy, bringing innovative approaches to vaccine development.

Innovation Initiatives:

• Advanced vaccine platform technologies

• Strategic partnerships enhancing vaccine access in emerging markets

---

4️⃣ 7. Sanofi Pasteur

Headquarters: Lyon, France
Key Offering: Integrated vaccine solutions including travel and endemic disease protection

Sanofi Pasteur leverages its extensive vaccine manufacturing expertise and global distribution network to provide comprehensive infectious disease protection.

Innovation Initiatives:

• Global manufacturing and cold chain distribution capabilities

• Support for public health initiatives in TBE-endemic countries

---

3️⃣ 8. Emergent BioSolutions Inc.

Headquarters: Gaithersburg, Maryland, USA
Key Offering: Travel vaccine portfolio with TBE prevention components

Emergent BioSolutions specializes in providing specialty vaccines and therapeutic products for public health threats.

Innovation Initiatives:

• Integrated vaccine development and manufacturing platform

• Commitment to addressing urgent public health needs through vaccine development

---

2️⃣ 9. Novartis AG

Headquarters: Basel, Switzerland
Key Offering: Specialized vaccine manufacturing and development services

The company focuses on developing and manufacturing vaccines with strategic partners, contributing to global vaccine supply security.

Innovation Initiatives:

• Vaccine manufacturing expertise and capacity expansion

• Advanced biologics manufacturing capabilities supporting vaccine production scale-up

---

1️⃣ 10. Mylan N.V. (now part of Viatris)

Headquarters: Canonsburg, Pennsylvania, USA
Key Offering: Generic and specialty pharmaceutical products including vaccine distribution services

Mylan, now part of Viatris, brought extensive pharmaceutical manufacturing and global distribution capabilities to the vaccine market.

Innovation Initiatives:

• Global pharmaceutical manufacturing and distribution infrastructure

• Broad access to healthcare markets in developing and developed regions

Get Full Report Here:
Tick-borne Encephalitis Inactivated Vaccine Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Tick-borne Encephalitis Prevention Is Smarter and More Accessible

The tick-borne encephalitis vaccine market is experiencing transformative changes. While traditional vaccine platforms continue to provide proven protection, the industry is advancing toward next-generation vaccine technologies, enhanced distribution networks, and improved public health education systems.

📈 Key Trends Shaping the Market:

• Increasing vaccination rates in high-risk European and Asian countries

• Regulatory emphasis on preventive healthcare in endemic regions

• Expansion of travel vaccination programs and occupational health initiatives

• Public-private partnerships expanding vaccine access to underserved populations

Get Full Report Here:
Tick-borne Encephalitis Inactivated Vaccine Market – View in Detailed Research Report

The companies listed above are not only protecting global populations—they’re spearheading the advancement of preventive healthcare against vector-borne diseases.